Therapeutic effect of N, N‐Diphenyl‐1,4‐phenylenediamine and adipose‐derived stem cells coadministration on diabetic cardiomyopathy in type 1 diabetes mellitus‐rat model

Abstract

AbstractType 1 diabetes stem‐cell‐based treatment approach is among the leading therapeutic strategies for treating cardiac damage owing to the stem cells' regeneration capabilities. Mesenchymal stem cells derived from adipose tissue (AD‐MSCs) have shown great potential in treating diabetic cardiomyopathy (DCM). Herein, we explored the antioxidant‐supporting role of N, N′‐diphenyl‐1,4‐phenylenediamine (DPPD) in enhancing the MSCs' therapeutic role in alleviating DCM complications in heart tissues of type 1 diabetic rats. Six male albinos Wistar rat groups have been designed into the control group, DPPD (250 mg/kg, i.p.) group, diabetic‐untreated group, and three diabetic rat groups treated with either AD‐MSCs (1 × 106 cell/rat, i.v.) or DPPD or both. Interestingly, all three treated diabetic groups exhibited a significant decrease in serum glucose, HbA1c, heart dysfunction markers (lactate dehydrogenase and CK‐MP) levels, and lipid profile fractions (except for HDL‐C), as well as some cardiac oxidative stress (OS) levels (MDA, AGEs, XO, and ROS). On the contrary, serum insulin, C‐peptide, and various cardiac antioxidant levels (GSH, GST, CAT, SOD, TAC, and HO‐1), beside viable cardiac cells (G0/G1%), were markedly elevated compared with the diabetic untreated group. In support of these findings, the histological assay reflected a marked enhancement in the cardiac tissues of all diabetic‐treated groups, with obvious excellency of the AD‐MSCs + DPPD diabetic‐treated group. Such results strongly suggested the great therapeutic potentiality of either DPPD or AD‐MSCs single injection in enhancing the cardiac function of diabetic rats, with a great noted enhancement superiority of DPPD and AD‐MSCs coadministration.